E. Ohman J:or Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-145,921
| Closed | -$1.68M | – | 426 |
|
|
2022
Q4 | $1.68M | Buy |
145,921
+49,157
| +51% | +$564K | 0.07% | 164 |
|
|
2022
Q3 | $1.22M | Sell |
96,764
-51,995
| -35% | -$655K | 0.06% | 205 |
|
|
2022
Q2 | $1.57M | Buy |
148,759
+50,000
| +51% | +$529K | 0.07% | 170 |
|
|
2022
Q1 | $1.61M | Sell |
98,759
-86,141
| -47% | -$1.4M | 0.05% | 203 |
|
|
2021
Q4 | $2.56M | Buy |
184,900
+53,800
| +41% | +$745K | 0.07% | 161 |
|
|
2021
Q3 | $1.88M | Buy |
131,100
+7,000
| +6% | +$101K | 0.06% | 188 |
|
|
2021
Q2 | $1.96M | Sell |
124,100
-20,000
| -14% | -$316K | 0.06% | 183 |
|
|
2021
Q1 | $1.47M | Buy |
144,100
+16,000
| +12% | +$163K | 0.05% | 203 |
|
|
2020
Q4 | $954K | Buy |
+128,100
| New | +$954K | 0.04% | 232 |
|